## Petar Seferovic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11532624/publications.pdf

Version: 2024-02-01

76326 182427 28,368 51 40 51 citations h-index g-index papers 51 51 51 23724 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
2	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	2.2	5,233
3	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	7.1	2,307
4	Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal, 2007, 29, 270-276.	2.2	2,280
5	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal, 2015, 36, 2921-2964.	2.2	1,768
6	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.2	1,758
7	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	2.2	944
8	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
9	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure. 2021. 23. 352-380.	7.1	630
10	European Society of Cardiology: Cardiovascular Disease Statistics 2017. European Heart Journal, 2018, 39, 508-579.	2.2	595
11	Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure, 2010, 12, 423-433.	7.1	593
12	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nature Reviews Cardiology, 2021, 18, 169-193.	13.7	589
13	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 1505-1535.	7.1	555
14	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Longâ€√erm Registry. European Journal of Heart Failure, 2013, 15, 1173-1184.	7.1	533
15	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 226-241.	7.1	455
16	Universal Definition and Classification of Heart Failure. Journal of Cardiac Failure, 2021, 27, 387-413.	1.7	362
17	Epidemiology, pathophysiology and contemporary management of cardiogenic shock–Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure 2020, 22, 1315-1341. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position	7.1	244
18	statement on behalf of the <scp>H</scp> eart <scp>F</scp> ailure <scp>A</scp> ssociation ( <scp>HFA</scp> , the <scp>E</scp> uropean <scp>A</scp> ssociation of <scp>C</scp> ardiovascular <scp>I</scp> maging ( <scp>EACVI</scp> ) and the <scp>Cardioâ€Oncology C</scp> ouncil of the <scp>E</scp> uropean <scp>S</scp> ociety of <scp>C</scp> ardiology ( <scp>ESC</scp> ). European Journal of Heart Failure, 2020, 22, 1504-1524.	7.1	234

#	Article	IF	CITATIONS
19	Evaluation of kidney function throughout the heart failure trajectory–Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 584-603.	7.1	213
20	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€Oncology Council of the European Society of Cardiology</scp> . European Journal of Heart Failure, 2020, 22, 1966-1983.	7.1	184
21	Selfâ€care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 157-174.	7.1	181
22	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD $\hat{a}\in$ Summary. Diabetes and Vascular Disease Research, 2014, 11, 133-173.	2.0	173
23	Acute heart failure congestion and perfusion status–Âimpact of the clinical classification on inâ€hospital and longâ€ŧerm outcomes; insights from the ESCâ€EORPâ€HFA Heart Failure Longâ€₹erm Registry. European Journal of Heart Failure, 2019, 21, 1338-1352.	7.1	170
24	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal, 2017, 38, 2649-2662.	2.2	163
25	Heart Failure Association of the European Society ofÂCardiology position paper on frailty in patients with heart failure. European Journal of Heart Failure, 2019, 21, 1299-1305.	7.1	144
26	Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 2022, 23, e34-e61.	1.2	140
27	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. European Journal of Heart Failure, 2018, 20, 879-887.	7.1	138
28	The <scp>Heart Failure Association Atlas</scp> : <scp>Heart Failure Epidemiology and Management Statistics</scp> 2019. European Journal of Heart Failure, 2021, 23, 906-914.	7.1	130
29	Heart Failure in Patients with Diabetes Mellitus. Cardiac Failure Review, 2017, 03, 52.	3.0	122
30	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 180-188.	3.0	113
31	Indications and practical approach to non-invasive ventilation in acute heart failure. European Heart Journal, 2018, 39, 17-25.	2.2	111
32	Under-representation of elderly and women in clinical trials. International Journal of Cardiology, 2017, 232, 216-221.	1.7	105
33	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	7.1	101
34	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. European Heart Journal, 2020, 41, 3787-3797.	2.2	101
35	Management of heart failure patients with <scp>COVID</scp> â€19: a joint position paper of the Chinese Heart Failure Association & Reart Failure Committee and the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 941-956.	7.1	95
36	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. European Heart Journal, 2022, 43, 1033-1058.	2.2	80

#	Article	IF	CITATIONS
37	Longâ€term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2018, 20, 332-341.	7.1	69
38	Sodium–glucose coâ€transporter 2 inhibitors as an early, firstâ€line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	7.1	67
39	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and highâ€risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314.	7.1	50
40	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction–Âinsights from the <scp>ESCâ€HFA EORP</scp> Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2022, 24, 335-350.	7.1	49
41	Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure. International Journal of Cardiology, 2016, 224, 191-198.	1.7	37
42	Sacubitril/valsartan eligibility and outcomes in the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGMâ€HF trial, ESC guidelines, and real world. European Journal of Heart Failure, 2019, 21, 1383-1397.	7.1	35
43	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. Cardiovascular Research, 2022, 118, 1385-1412.	3.8	27
44	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology ―Heart Failure Association EURObservational Research Programme Heart Failure Longâ€Term Registry. ESC Heart Failure, 2020, 7, 2098-2112.	3.1	23
45	The Heart Failure Association Atlas: rationale, objectives, and methods. European Journal of Heart Failure, 2020, 22, 638-645.	7.1	23
46	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1577-1596.	7.1	23
47	GuÃa de práctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Revista Espanola De Cardiologia, 2014, 67, 136.e1-136.e56.	1.2	15
48	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). European Heart Journal, 2022, 43, 2185-2195.	2.2	12
49	Renin inhibition in heart failure and diabetes: the real story. European Journal of Heart Failure, 2018, 20, 149-151.	7.1	7
50	2017 ESC guidelines focus on dual antiplatelet therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 131-132.	3.0	6
51	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. European Heart Journal Quality of Care & Dinical Outcomes, 2021, 7, 134-142.	4.0	3